The main research focus of the Brueggemann group is Streptococcus pneumoniae (the ‘pneumococcus’), a bacterium that is a major cause of diseases such as pneumonia and meningitis worldwide. Current research involves using high-throughput genotyping and whole genome sequencing techniques and unique collections of isolates to understand pneumococcal evolution, especially evolutionary changes related to antimicrobial and vaccine selective pressures. Molecular epidemiology and population biology provide the foundation for all aspects of the group’s research.
Our work has particular relevance to: i) understanding how antimicrobial resistance determinants evolve and spread; ii) long-term effectiveness of the existing pneumococcal conjugate vaccines; iii) the design of future vaccines; and iv) the development of novel antimicrobials.
Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data.
Brueggemann AB. et al, (2021), The Lancet. Digital health, 3, e360 - e370
Molecular diagnostic assays for the detection of common bacterial meningitis pathogens: A narrative review.
Diallo K. et al, (2021), EBioMedicine, 65
The global meningitis genome partnership.
Rodgers E. et al, (2020), The Journal of infection
Prophages and satellite prophages are widespread in Streptococcus and may play a role in pneumococcal pathogenesis.
Rezaei Javan R. et al, (2019), Nature communications, 10
Genomic Analyses of >3,100 Nasopharyngeal Pneumococci Revealed Significant Differences Between Pneumococci Recovered in Four Different Geographical Regions
van Tonder AJ. et al, (2019), FRONTIERS IN MICROBIOLOGY, 10